Literature DB >> 32063772

Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma.

James Lopez1, Naveen Yarlagadda1, Zaid Gheith1, Meera Mohan1, Appalanaidu Sasapu1.   

Abstract

Nivolumab, a monoclonal antibody against programmed cell death-1 used to treat multiple cancers, has fewer side effects than traditional chemotherapy but has displayed a propensity to cause a host of immune-related adverse events. We describe a case of nivolumab immune-mediated neurotoxicity in a 42-year-old Hispanic man with relapsed Hodgkin lymphoma who presented with unilateral facial droop, dysarthria, and dysphagia 1 week after receiving nivolumab. His symptoms rapidly improved with steroids, intravenous immunoglobulin, and infliximab.
Copyright © 2020 Baylor University Medical Center.

Entities:  

Keywords:  Hodgkin lymphoma; immune-mediated adverse reaction; neurotoxicity; nivolumab

Year:  2019        PMID： 32063772      PMCID： PMC6988700          DOI： 10.1080/08998280.2019.1668719

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


  12 in total

1.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Authors:  Tanya J Williams; David R Benavides; Kelly-Ann Patrice; Josep O Dalmau; Alexandre Leon Ribeiro de Ávila; Dung T Le; Evan J Lipson; John C Probasco; Ellen M Mowry
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302

2.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

Authors:  Peter Attia; Giao Q Phan; Ajay V Maker; Michael R Robinson; Martha M Quezado; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Nicholas P Restifo; Leah R Haworth; Catherine Levy; Sharon A Mavroukakis; Geoff Nichol; Michael J Yellin; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

3.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 4.  Plasma exchange for Guillain-Barré syndrome.

Authors:  Jean Claude Raphaël; Sylvie Chevret; Richard A C Hughes; Djillali Annane
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 5.  Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.

Authors:  Al-Ola Abdallah; Aline Herlopian; Rahul Ravilla; Meghana Bansal; Sowmya Chandra-Reddy; Fade Mahmoud; Shirley Ong; Murat Gokden; Laura Hutchins
Journal:  J Oncol Pharm Pract       Date:  2015-02-23       Impact factor: 1.809

6.  Peripheral neuropathy associated with ipilimumab: a report of 2 cases.

Authors:  Iyavut Thaipisuttikul; Paul Chapman; Edward K Avila
Journal:  J Immunother       Date:  2015 Feb-Mar       Impact factor: 4.456

7.  Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.

Authors:  Stephanie G Downey; Jacob A Klapper; Franz O Smith; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Tamika E Allen; Catherine L Levy; Michael Yellin; Geoffrey Nichol; Donald E White; Seth M Steinberg; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2007-11-02       Impact factor: 12.531

8.  Multifocal radiculoneuropathy during ipilimumab treatment of melanoma.

Authors:  Georgios Manousakis; James Koch; R Brian Sommerville; Ahmed El-Dokla; Matthew B Harms; Muhammad T Al-Lozi; Robert E Schmidt; Alan Pestronk
Journal:  Muscle Nerve       Date:  2013-07-27       Impact factor: 3.217

Review 9.  Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer.

Authors:  Jennifer Dine; RuthAnn Gordon; Yelena Shames; Mary Kate Kasler; Margaret Barton-Burke
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Apr-Jun

10.  Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.

Authors:  Christine A Garcia; Alex El-Ali; Tanya J Rath; Lydia C Contis; Vikram Gorantla; Jan Drappatz; Diwakar Davar
Journal:  J Immunother Cancer       Date:  2018-08-31       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.